The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Galinpepimut-S: mechanism of action and use in AML, ovarian cancer & mesothelioma
Wilms’ tumor gene (WT1) encodes a transcription factor that plays an important role in cell growth and differentiation, and is highly expressed in leukemia and various solid tumors. In this interview, Angelos M. Stergiou, MD, ScD, SELLAS Life Sciences Group, New York, NY, provides an overview of Wilms tumor 1 (WT1), as well as galinpepimut-S, a WT1-targeting immunotherapy that is comprised of four peptide chains that induce a strong innate immune response (CD4+/CD8+) against the WT1 antigen and across a broad range of HLA types. Dr Stergiou discusses current investigations evaluating GPS in patients with acute myeloid leukemia (AML), as well as ovarian cancer and mesothelioma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
